Personal information

Other IDs

Scopus Author ID: 36549161300

Activities

Collapse all

Employment (1)

Pharming Healthcare: Leiden, South Holland, NL

Employment
Source: Self-asserted source
Anurag Relan

Education and qualifications (4)

UCLA Health System: Los Angeles, CA, US

1999 to 2002 (Family Medicine)
Education
Source: Self-asserted source
Anurag Relan

University of California Los Angeles : Los Angeles, CA, US

1994 to 1999 | MD (School of Medicine)
Education
Source: Self-asserted source
Anurag Relan

University of California, Los Angeles: Los Angeles, CA, US

1996 to 1998 | MPH (School of Public Health)
Education
Source: Self-asserted source
Anurag Relan

University of California Berkeley: Berkeley, CA, US

1990 to 1994 | BA (Economics)
Education
Source: Self-asserted source
Anurag Relan

Works (50 of 73)

Items per page:
Page 1 of 2

A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS): Adolescent and adult subgroup analysis

Clinical Immunology
2025 | Journal article
DOI: 10.1016/j.clim.2024.110400
EID:

2-s2.0-85210272587

Part of ISSN: 15217035 15216616
Contributors: Rao, V.K.; Šedivá, A.; Dalm, V.A.S.H.; Plebani, A.; Schuetz, C.; Shcherbina, A.; Trizzino, A.; Zharankova, Y.; Orpia, A.; Kulm, E. et al.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Interim analysis: Open-label extension study of leniolisib for patients with APDS

Journal of Allergy and Clinical Immunology
2024 | Journal article
DOI: 10.1016/j.jaci.2023.09.032
EID:

2-s2.0-85174673820

Part of ISSN: 10976825 00916749
Contributors: Rao, V.K.; Kulm, E.; Šedivá, A.; Plebani, A.; Schuetz, C.; Shcherbina, A.; Dalm, V.A.; Trizzino, A.; Zharankova, Y.; Webster, S. et al.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Piloting an automated query and scoring system to facilitate APDS patient identification from health systems

Frontiers in Immunology
2024 | Journal article
DOI: 10.3389/fimmu.2024.1508780
EID:

2-s2.0-85216719408

Part of ISSN: 16643224
Contributors: FitzPatrick, A.M.; Chin, A.T.; Nirenberg, S.; Cunningham-Rundles, C.; Sacco, K.; Perlmutter, J.; Dasso, J.F.; Tsalatsanis, A.; Maru, J.; Creech, J. et al.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Recombinant Human C1 Esterase Inhibitor Treatment in Addition to Standard of Care for the Prevention of Cytokine Storm in Hospitalized Patients with COVID-19: A Randomized, Open-Label Trial

SSRN
2022 | Other
DOI: 10.2139/ssrn.4078179
EID:

2-s2.0-85179542712

Part of ISSN: 15565068
Contributors: Giannetti, B.; Guo, J.P.; Raslan, A.; Schaale, J.; Bulitta, M.; Relan, A.; Bernstein, J.A.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Randomized, Placebo-Controlled, Phase 3 Trial of PI3Kδ Inhibitor Leniolisib for Activated PI3Kδ Syndrome

Blood
2022-11-18 | Journal article | Author
DOI: 10.1182/blood.2022018546
Part of ISSN: 0006-4971
Part of ISSN: 1528-0020
Contributors: V. Koneti Rao; Sharon Webster; Anna Sediva; Alessandro Plebani; Catharina Schuetz; Anna Shcherbina; Niall Conlon; Tanya Iona Coulter; Virgil A. Dalm; Antonino Trizzino et al.
Source: Self-asserted source
Anurag Relan
grade
Preferred source (of 2)‎

Population pharmacokinetics of recombinant human C1 esterase inhibitor in children with hereditary angioedema

Annals of Allergy, Asthma and Immunology
2021 | Journal article
DOI: 10.1016/j.anai.2021.02.010
EID:

2-s2.0-85103414891

Part of ISSN: 15344436 10811206
Contributors: Hayes, S.; Farrell, C.; Relan, A.; Anderson, J.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry

World Allergy Organization Journal
2021 | Journal article
DOI: 10.1016/j.waojou.2021.100535
EID:

2-s2.0-85104577151

Part of ISSN: 19394551
Contributors: Valerieva, A.; Staevska, M.T.; Grivcheva-Panovska, V.; Jesenak, M.; Kőhalmi, K.V.; Hrubiskova, K.; Zanichelli, A.; Bellizzi, L.; Relan, A.; Hakl, R. et al.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Modeling Cost-effectiveness of on-demand treatment for hereditary angioedema attacks

Journal of Managed Care and Specialty Pharmacy
2020 | Journal article
DOI: 10.18553/jmcp.2019.19217
EID:

2-s2.0-85079018034

Part of ISSN: 23761032 23760540
Contributors: Bernstein, J.A.; Tyson, C.; Relan, A.; Adams, P.; Magar, R.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children

Pediatric Allergy and Immunology
2019 | Journal article
DOI: 10.1111/pai.13065
EID:

2-s2.0-85066607959

Part of ISSN: 13993038 09056157
Contributors: Reshef, A.; Grivcheva-Panovska, V.; Kessel, A.; Kivity, S.; Klimaszewska-Rembiasz, M.; Moldovan, D.; Farkas, H.; Gutova, V.; Fritz, S.; Relan, A. et al.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy

Journal of Allergy and Clinical Immunology: In Practice
2019 | Conference paper
DOI: 10.1016/j.jaip.2019.05.042
EID:

2-s2.0-85067687524

Part of ISSN: 22132198
Contributors: Moldovan, D.; Bernstein, J.A.; Hakl, R.; Porebski, G.; Poarch, K.; Lumry, W.R.; Relan, A.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

C1 esterase inhibitor concentrates and attenuated androgens – Authors' reply

The Lancet
2018 | Journal article
DOI: 10.1016/S0140-6736(18)30573-7
EID:

2-s2.0-85044957441

Part of ISSN: 1474547X 01406736
Contributors: Riedl, M.A.; Relan, A.; Harper, J.R.; Cicardi, M.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Efficacy of recombinant human C1 esterase inhibitor across anatomic locations in acute hereditary angioedema attacks

Allergy and Asthma Proceedings
2018 | Journal article
DOI: 10.2500/aap.2018.39.4151
EID:

2-s2.0-85054855239

Part of ISSN: 15396304 10885412
Contributors: Baker, J.W.; Bernstein, J.A.; Harper, J.R.; Relan, A.; Riedl, M.A.
Source: Self-asserted source
Anurag Relan via Scopus - Elsevier

Abstracts from the 10th C1-inhibitor deficiency workshop.

Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
2017 | Journal article
PMC: PMC5496025
Source: Self-asserted source
Anurag Relan via Europe PubMed Central

Efficacy of Recombinant Human C1 Esterase Inhibitor (rhC1INH) Across Anatomical Locations in Acute Hereditary Angioedema (HAE) Attacks

Journal of Allergy and Clinical Immunology
2017 | Journal article
Source: Self-asserted source
Anurag Relan

Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks

Allergy and Asthma Proceedings
2017 | Journal article
DOI: 10.2500/aap.2017.38.4088
Contributors: undefinedH. H. Li; undefinedA. Reshef; undefinedJ. W. Baker; undefinedJ. R. Harper; undefinedA. Relan
Source: Self-asserted source
Anurag Relan via Crossref Metadata Search
grade
Preferred source (of 2)‎

Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks

ALLERGY AND ASTHMA PROCEEDINGS
2017 | Conference paper
Source: Self-asserted source
Anurag Relan

Recombinant Human C1 Inhibitor (rHC1INH) Is Efficacious and Well Tolerated As Prophylaxis for Prevention of Hereditary Angioedema (HAE) Attacks: A Randomized, Phase 2 Trial

Journal of Allergy and Clinical Immunology
2017 | Journal article
Source: Self-asserted source
Anurag Relan

Recombinant Human C1-Esterase Inhibitor to Treat Acute Hereditary Angioedema Attacks in Adolescents.

The journal of allergy and clinical immunology. In practice
2017 | Journal article
DOI: 10.1016/j.jaip.2016.11.005
PMID: 28202404
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

WAO International Scientific Conference (WISC 2016) Abstracts: Jerusalem, Israel. 6–9 December 2016.

The World Allergy Organization journal
2017 | Journal article
PMC: PMC5499101
Contributors: Bao J; Wang Y; Liu Q; Bao Y; Azouz N; Caldwell J; Ray L; Rochman M; Mingler M; Eilerman M et al.
Source: Self-asserted source
Anurag Relan via Europe PubMed Central

Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement.

Allergy and asthma proceedings
2017-09 | Journal article
DOI: 10.2500/aap.2017.38.4090
PMID: 28903805
Contributors: Riedl MA; Li H; Cicardi M; Harper JR; Relan A
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial

The Lancet
2017-07 | Journal article
DOI: 10.1016/s0140-6736(17)31963-3
Contributors: Marc A Riedl; Vesna Grivcheva-Panovska; Dumitru Moldovan; James Baker; William H Yang; Bruno M Giannetti; Avner Reshef; Sladjana Andrejevic; Richard F Lockey; Roman Hakl et al.
Source: Self-asserted source
Anurag Relan via Crossref Metadata Search
grade
Preferred source (of 2)‎

Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
2017-04 | Journal article
DOI: 10.1016/j.anai.2017.01.029
PMID: 28284978
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

Allergenicity and safety of rhC1INH in patients with allergy to rabbit or cow's milk

ALLERGY
2016 | Conference paper
Source: Self-asserted source
Anurag Relan

C1 inhibitor limits organ injury and prolongs survival in swine subjected to battlefield simulated injury

Shock
2016 | Journal article
DOI: 10.1097/SHK.0000000000000677
EID:

2-s2.0-84978112713
Source: Self-asserted source
Anurag Relan
grade
Preferred source (of 2)‎

O001 Randomized, double-blind, placebo-controlled trial of recombinant human C1 inhibitor for prophylaxis of hereditary angioedema attacks

Annals of Allergy, Asthma & Immunology
2016 | Journal article
Source: Self-asserted source
Anurag Relan

Allergenicity and safety of recombinant human C1 esterase inhibitor in patients with allergy to rabbit or cow's milk.

The Journal of allergy and clinical immunology
2016-08 | Journal article
DOI: 10.1016/j.jaci.2016.04.019
PMID: 27321437
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

Angioedema attacks in patients with hereditary angioedema: Local manifestations of a systemic activation process.

The Journal of allergy and clinical immunology
2016-08 | Journal article
DOI: 10.1016/j.jaci.2016.02.041
PMID: 27246526
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

EFFICACY OF RHC1INH FOR THE TREATMENT OF PERIPHERAL ANGIOEDEMA IN PATIENTS WITH HAE

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2015 | Conference paper
Source: Self-asserted source
Anurag Relan

Manifestations locales au cours d�un processus systémique: modèle pathogénique de l�angiœdème à bradykinine (AOBK)

Revue Française d'Allergologie
2015 | Journal article
Source: Self-asserted source
Anurag Relan

Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks.

The journal of allergy and clinical immunology. In practice
2015 | Journal article
DOI: 10.1016/j.jaip.2014.12.013
PMID: 25680925
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

SAFETY AND EFFICACY OF RHC1INH FOR THE TREATMENT OF HAE ATTACKS IN PEDIATRIC PATIENTS

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2015 | Conference paper
Source: Self-asserted source
Anurag Relan

Treatment of bleeding with low half-life fibrinogen

2015-12 | Other
Source: Self-asserted source
Anurag Relan

Elevated D-dimers in attacks of hereditary angioedema are not associated with increased thrombotic risk.

Allergy
2015-05 | Journal article
DOI: 10.1111/all.12587
PMID: 25640891
PMC: PMC4409094
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

EFFICACY OF RECOMBINANT HUMAN C1 INHIBITOR FOR THE TREATMENT OF HEREDITARY ANGIOEDEMA PATIENTS WITH SEVERE ATTACKS.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2014 | Conference paper
Source: Self-asserted source
Anurag Relan

Hereditary Angioedema Attacks: Local Swelling at Multiple Sites

Clinical Reviews in Allergy & Immunology
2014 | Journal article
DOI: 10.1007/s12016-014-8463-6
Contributors: Zonne L. M. Hofman; Anurag Relan; C. Erik Hack
Source: Self-asserted source
Anurag Relan via Crossref Metadata Search
grade
Preferred source (of 2)‎

Recombinant Human C1 Inhibitor Treatment Does Not Affect D-Dimer Levels and Is Not Associated With Thromboembolic Events In HAE Patients

Journal of Allergy and Clinical Immunology
2014 | Journal article
Source: Self-asserted source
Anurag Relan

Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial

Annals of Allergy, Asthma & Immunology
2014 | Journal article
DOI: 10.1016/j.anai.2013.12.004
PMID: 24468257
EID:

2-s2.0-84893684243
Source: Self-asserted source
Anurag Relan
grade
Preferred source (of 3)‎

Sustained response following acute treatment of hereditary angioedema attacks with recombinant human C1 esterase inhibitor

Journal of Allergy and Clinical Immunology
2014 | Journal article
Source: Self-asserted source
Anurag Relan

TREATMENT WITH RECOMBINANT HUMAN C1 INHIBITOR SHORTENS DURATION OF HEREDITARY ANGIOEDEMA ATTACK SYMPTOMS.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2014 | Conference paper
Source: Self-asserted source
Anurag Relan

C-reactive protein levels in hereditary angioedema.

Clinical and experimental immunology
2014-07 | Journal article
DOI: 10.1111/cei.12314
PMID: 24588117
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

Abdominal Presentation of Acute Attacks of Hereditary Angioedema and Efficacy of Recombinant C1 Inhibitor in Symptom Resolution

AMERICAN JOURNAL OF GASTROENTEROLOGY
2013 | Conference paper
Source: Self-asserted source
Anurag Relan

Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study

Annals of Allergy, Asthma & Immunology
2013 | Journal article
DOI: 10.1016/j.anai.2013.02.007
PMID: 23535096
EID:

2-s2.0-84875436177
Source: Self-asserted source
Anurag Relan
grade
Preferred source (of 3)‎

EFFICACY AND SAFETY OF RECOMBINANT HUMAN C1 ESTERASE INHIBITOR FOR ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA: AN OPEN-LABEL STUDY

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
2013 | Conference paper
Source: Self-asserted source
Anurag Relan

Hereditary Angioedema

Journal der Deutschen Dermatologischen Gesellschaft
2013 | Conference paper
Source: Self-asserted source
Anurag Relan

Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IgE antibodies

Clinical drug investigation
2013 | Journal article
DOI: 10.1007/s40261-013-0064-2
EID:

2-s2.0-84877039218
Source: Self-asserted source
Anurag Relan
grade
Preferred source (of 3)‎

Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study

Allergy
2013 | Journal article
DOI: 10.1111/all.12060
PMID: 23121116
EID:

2-s2.0-84870589984
Source: Self-asserted source
Anurag Relan
grade
Preferred source (of 3)‎

Recombinant human C1 inhibitor for treatment of acute attacks of hereditary angioedema: a randomised, double-blind, placebo-controlled clinical trial

Allergy: European Journal of Allergy and Clinical Immunology
2013 | Journal article
Source: Self-asserted source
Anurag Relan

Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema.

British journal of clinical pharmacology
2013-12 | Journal article
DOI: 10.1111/bcp.12132
PMID: 23594263
PMC: PMC3845313
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study.

The patient
2012 | Journal article
DOI: 10.2165/11597490-000000000-00000
PMID: 22462765
Source: Self-asserted source
Anurag Relan via Europe PubMed Central
grade
Preferred source (of 2)‎

Efficacy and safety of a weekly infusion of recombinant human C1 inhibitor (rhc1inh) for the prophylaxis of hereditary angioedema attacks

Allergy: European Journal of Allergy and Clinical Immunology
2012 | Journal article
Source: Self-asserted source
Anurag Relan
Items per page:
Page 1 of 2
How many people are using ORCID?